Registered title, quoted from ClinicalTrials.gov
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page
- Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07896005, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Patients with histologically confirmed locally advanced or metastatic non-squamous NSCLC.
Inclusion criterion 4
Participants with HER2 overexpression confirmed by a central laboratory.
Inclusion criterion 5
ECOG score of 0 or 1.
Inclusion criterion 3
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07896005, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Able to provide informed consent, willing and able to comply with the scheduled visits, examinations, and other procedural requirements of the treatment.
- Aged 18-75 years (inclusive) at the time of signing the informed consent form, with no restriction on sex.
- ECOG score of 0 or 1.
- Patients with histologically confirmed locally advanced or metastatic non-squamous NSCLC.
- Participants with HER2 overexpression confirmed by a central laboratory.
- Have not previously received systemic antitumor therapy for locally advanced or metastatic NSCLC.
Exclusion Criteria:
- Participants with untreated or active metastasis of central nervous system (CNS) tumors, or a history of meningeal metastasis or current meningeal metastasis.
- Previous or current with other malignancies.
- Prior antitumor toxicity and/or complications have not recovered to NCI-CTCAE ≤ Grade 1.
- Currently participating in another clinical study, or the interval between the start of study treatment and the end of the previous clinical study is less than specified period.
- Participants with active or previous autoimmune diseases.
- Participants with uncontrolled or severe cardiovascular diseases.
- Participants with active hepatitis B or hepatitis C.
Quoted from ClinicalTrials.gov, NCT07896005, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07896005, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.